<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087022</url>
  </required_header>
  <id_info>
    <org_study_id>WX-2003-07-HR</org_study_id>
    <secondary_id>WILEX-WX-2003-07-HR</secondary_id>
    <secondary_id>ARISER</secondary_id>
    <secondary_id>UCLA-0404015-01</secondary_id>
    <secondary_id>CDR0000372830</secondary_id>
    <secondary_id>NCI-2012-00491</secondary_id>
    <nct_id>NCT00087022</nct_id>
    <nct_alias>NCT00209183</nct_alias>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer</brief_title>
  <official_title>A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wilex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wilex</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
      tumor-killing substances to them without harming normal cells. It is not yet known whether
      monoclonal antibody therapy is effective in treating kidney cancer.

      PURPOSE: This randomized phase III trial is studying monoclonal antibody therapy to see how
      well it works in treating patients who have undergone surgery for nonmetastatic primary
      kidney cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the disease-free and overall survival of patients with primary clear cell renal
           cell carcinoma at high risk for recurrence treated with chimeric monoclonal antibody
           cG250 (WX-G250) vs placebo in an adjuvant setting.

      Secondary

        -  Evaluate the safety of these drugs in these patients.

        -  Assess the quality of life of patients treated with this drug.

        -  Perform pharmacokinetic analysis of WX-G250.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to risk criteria and participating centers (US vs Non-US). Patients
      are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive monoclonal chimeric antibody cG250 (WX-G250) IV over 15 minutes
           once weekly for 24 weeks.

        -  Arm II: Patients receive placebo IV over 15 minutes once weekly for 24 weeks. In both
           arms, treatment continues in the absence of disease progression or unacceptable
           toxicity.

      Blood samples are collected for pharmacokinetic analysis.

      Quality of life is assessed at baseline, at weeks 12 and 24 during treatment, and then at 6
      months after completion of study treatment.

      Patients are followed every 3 months during years 1 and 2, every 6 months during years 3 and
      4, and then annually during year 5 and thereafter.

      PROJECTED ACCRUAL: A total of 864 patients out of the expected 856 (428 per treatment arm)
      were accrued for this trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>Until signs of recurrence or until 360 local DFS events have occurred (median follow-up of 4.5 years)</time_frame>
    <description>Disease Free Survival (DFS) calculated from the date of randomization up to and including the date of documented relapse as confirmed by the CT, death or start of new anti-tumor therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>After 419 OS events or 60 months after the last patient has been enrolled, whichever is the later (median follow-up of 4.5 years)</time_frame>
    <description>Overall Survival (OS) calculated from the date of randomization to the date of death. Patients with no documented death will be censored at the date of their last study evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Global Health Status</measure>
    <time_frame>At 12 months</time_frame>
    <description>Quality of life by EORTC Quality of Life Questionnaire-C30 - Global Health Status at 12 months. A high score for the global health status/QoL represents a high QoL with 0 being the minimum and 100 being the maximum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of WX-G250</measure>
    <time_frame>Week 8</time_frame>
    <description>Quantitative determination of cG250 (Girentuximab) trough serum profiles at week 8 (steady state concentration).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">864</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive monoclonal chimeric antibody cG250 (synonym names: Rencarex®, girentuximab, and WX-G250) IV over 15 minutes once weekly for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo IV over 15 minutes once weekly for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>girentuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Rencarex®, cG250 and WX-G250</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary clear cell renal cell carcinoma

               -  Meets 1 of the following high risk criteria:

                    -  T3a, N0/NX, M0 OR T3b, N0/NX, M0 OR T3c, N0/NX, M0 OR T4, N0/NX, M0

                    -  Any T stage and N + disease and M0

                    -  T1b, N0/NX, M0 OR T2, N0/NX, M0, each with grade ≥ 3 (Fuhrman or any other
                       nuclear grading system with at least 3 grades)

          -  Prior nephrectomy (total or partial) of primary renal cell carcinoma with documented
             clear cell histology within the past 12 weeks

               -  No evidence of macroscopic or microscopic residual disease

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Platelet count &gt; 100,000/mm^3

          -  WBC &gt; 3,000/mm^3

          -  Hemoglobin &gt; 10 g/dL

        Hepatic

          -  AST and ALT &lt; 3 times upper limit of normal (ULN)

          -  Bilirubin &lt; 1.5 times ULN

          -  Hepatitis B surface antigen (HbsAg) negative

          -  Hepatitis C antibody negative

        Renal

          -  Creatinine &lt; 2.0 times ULN

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV I and II negative

          -  No concurrent unrelated illness which can significantly jeopardize patients' clinical
             status

          -  No active infection

          -  No inflammation

          -  No medical condition or laboratory abnormalities that would preclude study
             participation

          -  No other malignancies within the past 5 years except surgically cured nonmelanoma skin
             cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 5 years since prior immunotherapy

          -  No prior murine or chimeric antibody therapy

        Chemotherapy

          -  More than 5 years since prior chemotherapy

        Endocrine therapy

          -  No concurrent corticosteroids above Cushing dose for another disease

               -  Physiologic corticosteroid replacement therapy allowed at discretion of the
                  primary investigator

        Radiotherapy

          -  More than 5 years since prior radiotherapy

        Surgery

          -  See Disease Characteristics

          -  No prior organ transplantation

        Other

          -  No concurrent immunosuppressive agents (e.g., cyclosporine or tacrolimus)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pia Kloepfer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wilex</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arie Belldegrun, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen F. Graham Cancer Center at Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Urological Associates - Daytona Beach</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Group</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta Oncology Associates - Walton Way</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Idaho Urology - Coeur d'Alene</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814-2668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Indiana Urology, PC</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Specialists, LLC - Metairie</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feist-Weiller Cancer Center at Louisiana State University Health Sciences</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Werner-Francis Urology Associates, LLC</name>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <zip>20770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Medical Center - Burlington</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Care Physicians, PC at Urological Institute of NENY</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of Mercy Medical Center Comprehensive Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Urology, PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Urology Specialists - Greensboro</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital Cancer Care</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214-3998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Associates of Lancaster, Limited</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center at Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates of South Texas, PA</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio, PA - Fredericksburg</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Cancer Center at University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405-0110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Virginia Mason Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Alexander Fleming</name>
      <address>
        <city>Cramer</city>
        <state>Buenos Aires</state>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Zonal General de Agudos</name>
      <address>
        <city>Ranelagh</city>
        <state>Buenos Aires</state>
        <zip>1886</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Medico de la Policia Federal Argentina</name>
      <address>
        <city>Buenos Aires</city>
        <state>Capital Federal</state>
        <zip>1424</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Oncologica Del Neuquen</name>
      <address>
        <city>Neuquen</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Oncologia Rosario</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Especializada ISIS</name>
      <address>
        <city>Santa Fe</city>
        <zip>S300FFV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biocancer Centro de Pesq e Trat de Cancer SA</name>
      <address>
        <city>Belo-Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30240-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nucleo de Oncologia da Bahia</name>
      <address>
        <city>Bahia</city>
        <zip>40170-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancer</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20230-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sirio-Libanes</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04023-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G. Steinhoff Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Institute of Urology at St. Joseph Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Male Health Centre - Oakville</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3PI</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMX Research, Incorporated</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 3J3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Male Health Centre - North York</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A 3B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Lemoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <results_first_submitted>July 2, 2018</results_first_submitted>
  <results_first_submitted_qc>August 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 12, 2018</results_first_posted>
  <disposition_first_submitted>January 28, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 28, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 28, 2014</disposition_first_posted>
  <last_update_submitted>October 31, 2018</last_update_submitted>
  <last_update_submitted_qc>October 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clear cell renal cell carcinoma</keyword>
  <keyword>stage I renal cell cancer</keyword>
  <keyword>stage II renal cell cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Patients receive monoclonal chimeric antibody cG250 (synonym names: Rencarex, girentuximab, and WX-G250) IV over 15 minutes as a single loading dose of 50 mg (week 1) followed by weekly infusions of 20 mg of WX-G250 (weeks 2-24).
girentuximab: Given IV</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients receive placebo IV over 15 minutes once weekly for 24 weeks.
placebo: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="433"/>
                <participants group_id="P2" count="431"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated (Safety Population)</title>
              <participants_list>
                <participants group_id="P1" count="431"/>
                <participants group_id="P2" count="424"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="379"/>
                <participants group_id="P2" count="376"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients that were enrolled were included in the ITT population used for efficacy analysis; only 855 patients received at least one dose of study treatment and were analyzed for safety (Safety Population, SP)</population>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Patients receive monoclonal chimeric antibody cG250 (WX-G250) IV over 15 minutes as a single loading dose of 50 mg (week 1) followed by weekly infusions of 20 mg of WX-G250 (weeks 2-24).
girentuximab: Given IV</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients receive placebo IV over 15 minutes once weekly for 24 weeks.
placebo: Given IV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="433"/>
            <count group_id="B2" value="431"/>
            <count group_id="B3" value="864"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.2" spread="9.83"/>
                    <measurement group_id="B2" value="57.8" spread="10.1"/>
                    <measurement group_id="B3" value="58.0" spread="9.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="298"/>
                    <measurement group_id="B3" value="574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival</title>
        <description>Disease Free Survival (DFS) calculated from the date of randomization up to and including the date of documented relapse as confirmed by the CT, death or start of new anti-tumor therapy.</description>
        <time_frame>Until signs of recurrence or until 360 local DFS events have occurred (median follow-up of 4.5 years)</time_frame>
        <population>All patients that were enrolled were included in the ITT population used for efficacy analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients receive monoclonal chimeric antibody cG250 (WX-G250) IV over 15 minutes as a single loading dose of 50 mg (week 1) followed by weekly infusions of 20 mg of WX-G250 (weeks 2-24).
girentuximab: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo IV over 15 minutes once weekly for 24 weeks.
placebo: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Disease Free Survival (DFS) calculated from the date of randomization up to and including the date of documented relapse as confirmed by the CT, death or start of new anti-tumor therapy.</description>
          <population>All patients that were enrolled were included in the ITT population used for efficacy analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.737</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall Survival (OS) calculated from the date of randomization to the date of death. Patients with no documented death will be censored at the date of their last study evaluation.</description>
        <time_frame>After 419 OS events or 60 months after the last patient has been enrolled, whichever is the later (median follow-up of 4.5 years)</time_frame>
        <population>All patients that were enrolled were included in the ITT population used for efficacy analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients receive monoclonal chimeric antibody cG250 (WX-G250) IV over 15 minutes as a single loading dose of 50 mg (week 1) followed by weekly infusions of 20 mg of WX-G250 (weeks 2-24).
girentuximab: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo IV over 15 minutes once weekly for 24 weeks.
placebo: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall Survival (OS) calculated from the date of randomization to the date of death. Patients with no documented death will be censored at the date of their last study evaluation.</description>
          <population>All patients that were enrolled were included in the ITT population used for efficacy analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.012</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Global Health Status</title>
        <description>Quality of life by EORTC Quality of Life Questionnaire-C30 - Global Health Status at 12 months. A high score for the global health status/QoL represents a high QoL with 0 being the minimum and 100 being the maximum.</description>
        <time_frame>At 12 months</time_frame>
        <population>Patients still on study who completed the questionnaire</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients receive monoclonal chimeric antibody cG250 (WX-G250) IV over 15 minutes as a single loading dose of 50 mg (week 1) followed by weekly infusions of 20 mg of WX-G250 (weeks 2-24).
girentuximab: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo IV over 15 minutes once weekly for 24 weeks.
placebo: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Global Health Status</title>
          <description>Quality of life by EORTC Quality of Life Questionnaire-C30 - Global Health Status at 12 months. A high score for the global health status/QoL represents a high QoL with 0 being the minimum and 100 being the maximum.</description>
          <population>Patients still on study who completed the questionnaire</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="21"/>
                    <measurement group_id="O2" value="71" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of WX-G250</title>
        <description>Quantitative determination of cG250 (Girentuximab) trough serum profiles at week 8 (steady state concentration).</description>
        <time_frame>Week 8</time_frame>
        <population>Patients who did sign amendment #3 to the study protocol and received their cG250 infusion as scheduled in the study protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients receive monoclonal chimeric antibody cG250 (WX-G250) IV over 15 minutes as a single loading dose of 50 mg (week 1) followed by weekly infusions of 20 mg of WX-G250 (weeks 2-24).
girentuximab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of WX-G250</title>
          <description>Quantitative determination of cG250 (Girentuximab) trough serum profiles at week 8 (steady state concentration).</description>
          <population>Patients who did sign amendment #3 to the study protocol and received their cG250 infusion as scheduled in the study protocol</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Disease Free Survival (DFS) for Patients With CAIX Score &gt;= 2.6</title>
        <description>This analysis includes patients having a CAIX Expression equal or above the CAIX score of 2.6.
The CAIX score is determined on the basis of CAIX expression via immunohistochemistry described by a combination of tumor cell extent and staining intensity.
Disease Free Survival (DFS) calculated from the date of randomization up to and including the date of documented relapse as confirmed by the CT, death or start of new anti-tumor therapy.</description>
        <time_frame>Until signs of recurrence or until 360 local DFS events have occurred (median follow-up of 4.5 years)</time_frame>
        <population>This analysis includes patients having a CAIX Expression equal or above the CAIX score of 2.6.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients receive monoclonal chimeric antibody cG250 (WX-G250) IV over 15 minutes as a single loading dose of 50 mg (week 1) followed by weekly infusions of 20 mg of WX-G250 (weeks 2-24).
girentuximab: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo IV over 15 minutes once weekly for 24 weeks.
placebo: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS) for Patients With CAIX Score &gt;= 2.6</title>
          <description>This analysis includes patients having a CAIX Expression equal or above the CAIX score of 2.6.
The CAIX score is determined on the basis of CAIX expression via immunohistochemistry described by a combination of tumor cell extent and staining intensity.
Disease Free Survival (DFS) calculated from the date of randomization up to and including the date of documented relapse as confirmed by the CT, death or start of new anti-tumor therapy.</description>
          <population>This analysis includes patients having a CAIX Expression equal or above the CAIX score of 2.6.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Patients receive monoclonal chimeric antibody cG250 (WX-G250) IV over 15 minutes as a single loading dose of 50 mg (week 1) followed by weekly infusions of 20 mg of WX-G250 (weeks 2-24).
girentuximab: Given IV</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients receive placebo IV over 15 minutes once weekly for 24 weeks.
placebo: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ADHESIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILIARY DILATATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>EMPYEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>MENISCUS LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BIOPSY LUNG</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>MEDIASTINOSCOPY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>PATHOLOGICAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>METASTASES TO CENTRAL NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>METASTASES TO LUNG</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>METASTASES TO LYMPH NODES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>RECURRENT CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>THYROID NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>PERIPHERAL NERVE LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>OVARIAN MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>COLON POLYPECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>MALIGNANT TUMOUR EXCISION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>RENAL TUMOUR EXCISION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>THYROID OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of R&amp;D</name_or_title>
      <organization>Heidelberg Pharma AG (previously Wilex AG)</organization>
      <email>info@hdpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

